Shopping Cart 0
Cart Subtotal
USD 0

Allergan Plc (AGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology, women's health, urology and anti-infective therapeutic categories. The company sells its products to retailers, drug wholesalers and distributors, including national retail drug and food store chains, mail order retailers, hospitals, clinics, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. It has operations in several countries across the Americas, Europe, Asia-Pacific, the Middle East and Africa. Allergan is headquartered in Dublin, Ireland.

Allergan Plc (AGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 9

List of Figures 12

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14

Allergan Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 15

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 17

Allergan Plc, Medical Devices Deals, 2012 to YTD 2018 19

Allergan Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 20

Allergan Plc, Pharmaceuticals & Healthcare, Deal Details 33

Asset Purchase 33

Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 33

Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 34

Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 36

Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For USD 55 Million 37

Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 38

Venture Financing 39

Chase Pharma Raises USD12 Million in Financing Round 39

Chase Pharma Raises Additional USD0.5 Million in Venture Financing 40

Akarna Therapeutics Raises USD15 Million in Series B Financing 41

Rhythm Pharma Raises Additional USD15 Million in Series A Financing Round 42

RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 43

Chase Pharma Raises USD3 Million in Venture Financing 44

RetroSense Therapeutics Raises USD6 Million in Series A Financing 45

Naurex Raises USD80 Million in Series C Venture Financing 46

Colorescience Raises USD15 Million in Series B Venture Financing 48

Chase Pharma Raises USD21 Million in Series B Financing 49

Naurex Raises USD 25 Million In Venture Financing 50

Topokine Therapeutics Raises Funds Through Venture Financing 52

Rhythm Holding Raises USD 11 Million In Venture Financing 53

Colorescience Raises USD 10 Million In Series A Financing 54

Anterios Raises USD 8.5 Million In Venture Financing 55

Anterios Raises USD 4.7 Million In Venture Financing 56

Topokine Therapeutics Raises Funds Through Venture Financing 57

Colorescience Raises USD 15 Million In Venture Financing 58

Regado Biosciences Raises USD 51 Million In Series E Financing 59

Naurex Raises USD 38 Million In Series B Financing 61

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 63

Rhythm Pharma Raises USD 33 Million In Series B Financing 65

Rhythm Pharma Raises USD 9.5 Million In Venture Financing 67

Uteron Pharma Raises USD 10.4 Million In Venture Financing 68

Regado Biosciences Raises USD 6.8 Million In Venture Financing 69

Motus Therapeutics Secures USD25 Million in Series B Round of Venture Funding 70

Uteron Pharma Raises USD 19 Million In Venture Financing 71

SkinMedica Raises USD 16.8 Million In Venture Financing 72

Private Equity 73

Allergan May Divest its Women's Health Business 73

TPG Capital Acquires Aptalis Pharma from Actavis 74

Partnerships 75

Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 75

Lyndra Enters into Agreement with Allergan 76

Allergan to Enter into Partnership with Target PharmaSolutions 77

Allergan Enters into Agreement with Novartis 78

Allergan Pharma Enters into Research Agreement with Editas Medicine 79

Gedeon Richter Enters into Distribution Agreement with Allergan 80

T2 Biosystems Enters into Agreement with Allergan 81

Amgen Enters into Agreement with Allergan 82

Allergan Enters into Co-Development Agreement with AstraZeneca 83

Galderma Enters into Agreement with ZELTIQ Aesthetics 84

Allergan Enters into Agreement with Rugen Therapeutics 85

Allergan Enters into Research Agreement with Humana 86

NuMedii Enters into Research Agreement with Allergan 87

Aptinyx to Enter into Research Partnership with Allergan 88

Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 89

Molecular Partners Reinforces Partnership with Allergan 90

Allergan Enters into Distribution Agreement with WhanIn Pharma 91

Particle Sciences Enters Into Co-Development Agreement With Actavis 92

Voyant Biotherapeutics Enters Into R&D Agreement With Allergan For Ocular Disease 93

Merrimack Pharma Amends Co-Development Agreement With Actavis 94

Amerigen Pharma Enters Into Co-Development Agreement With Forest Labs For Specialty Generic Products 95

Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 96

Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 97

Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 98

Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 99

Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 100

Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 101

Allergan Exercises Option Agreement with Molecular Partners 102

American Medical Systems Enters Into Co-Development Agreement With Allergan 103

Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 104

ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 105

Merger 106

Regado Biosciences Merges with Tobira Therapeutics 106

Licensing Agreements 108

Syndax Pharma Enters into Licensing Agreement with Vitae Pharma 108

Allergan Enters into Licensing Agreement with Saint Regis Mohawk Tribe 109

Allergan Enters into Licensing Agreement with Assembly Biosciences 110

Allergan Enters Into Licensing Agreement With UroGen Pharma 112

Allergan Enters into Licensing Agreement with AstraZeneca 113

RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 114

Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 115

Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 116

Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 117

Allergan Amends Licensing Agreement with Heptares Therapeutics 118

Rhythm Pharma Enters into Licensing Agreement with Camurus 119

Allergan Enters into Licensing Agreement with Mimetogen Pharma 120

Allergan Enters into Licensing Agreement with Almirall for Constella 121

Apricus Biosciences Enters into Licensing Agreement with Allergan 122

Allergan Enters into Licensing Agreement with Merck 123

Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 124

Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 125

Durata Therapeutics Enters into Licensing Agreement with Angelini for Dalvance 126

Allergan Enters Into Licensing Agreement With Medytox For Neurotoxin Product 127

RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 128

Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 129

Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 130

Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 131

Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 132

Angelini Enters into Licensing Agreement with Allergan 133

Forest Labs Amends Licensing Agreement With moksha8 For Viibryd 134

InnoCore Enters Into Licensing Agreement With Allergan 135

Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 136

Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 137

Watson Pharma Enters Into Licensing Agreement With moksha8 Pharma For Five Generic Central Nervous System Products 138

Forest Labs Enters Into Licensing Agreement With moksha8 For Viibryd 139

Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 140

QrxPharma Enters Into Licensing Agreement With Actavis For MoxDuo IR 141

Equity Offering 143

Allergan Files Registration Statement for Public Offering of Securities 143

Vitae Pharma Raises USD35 Million in Public Offering of Shares 144

Aptinyx Spin Off from Naurex 146

Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 147

Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 148

Anterios Postpones IPO for up to USD54.6 Million 149

Kythera Biopharma Raises USD143.8 Million in Public Offering of Shares 150

Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 152

Actavis Raises USD4.18 Billion in Public Offering of Shares 154

Vitae Pharma Raises USD41 Million in Public Offering of Shares 156

Vitae Pharmaceuticals Completes Exercise of Underwriter's Over Allotment Option for IPO for USD63.3 Million 158

Tobira Therapeutics Withdraws IPO 160

Regado Biosciences Completes Public Offering Of Shares For USD 60 Million 162

Regado Biosciences Completes Private Placement Of Shares For USD 20 Million 164

Furiex Pharma Files Registration Statement For Public Offering Of Securities For USD 100 Million 165

Kythera Biopharma Completes Underwriters' Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 133.5 Million 166

Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For USD 43 Million 168

Durata Therapeutics Completes Public Offering Of Shares For USD 58 Million 170

Kythera Biopharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 81 Million 172

MAP Pharma Completes Public Offering Of Common Stock For USD 60 Million 174

Forest Labs Plans Rights Offering Of Common Stock 175

Durata Therapeutics Completes IPO For USD 78 Million 176

Debt Offering 178

Allergan Raises USD817.8 Million in Public Offering of 0.5% Notes Due 2021 178

Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 179

Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 180

Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 181

Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 182

Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2045 183

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2016 185

Actavis Raises USD4 Billion in Public Offering of Senior Notes Due 2025 187

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2020 189

Actavis Raises USD1 Billion in Public Offering of Senior Notes Due 2017 191

Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2022 193

Actavis Raises USD3.5 Billion in Public Offering of Senior Notes Due 2020 195

Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2035 197

Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2018 199

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2018 201

Forest Lab Completes Private Placement Of Notes Due 2021 For USD 750 Million 203

Forest Lab Completes Private Placement Of Notes Due 2019 For USD 1.05 Billion 204

Forest Labs Completes Private Placement Of Notes Due 2021 For USD 1.2 Billion 205

Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For USD 25 Million 206

Watson Pharma Completes Public Offering Of Notes Due 2022 For USD 1.7 Billion 207

Watson Pharma Completes Public Offering Of Notes Due 2017 For USD 1.2 Billion 209

Watson Pharma Completes Public Offering Of Notes Due 2042 For USD 1 Billion 211

Asset Transactions 213

Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 213

Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 215

Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 217

Ropack Acquires Two Pharma Facilities in Long Island, New York from Forest Labs 219

AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 220

Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 221

Mithra Pharma Acquires Women Health Portfolio from Uteron Pharma 222

Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 223

Impax Labs Acquires Two Generic Products from Actavis 224

G&W Labs Acquires Facility in Lincoln County, North Carolina from Actavis 225

Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For USD 40.8 Million 226

Mayne Pharma Acquires Brands And Related Assets For Forest Labs For USD 12 Million 228

Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 229

Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 231

Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 233

Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 234

Harvard Drug Group Completes Acquisition Of Rugby OTC Portfolio Of Watson Pharma For USD 117 Million 236

Acquisition 238

Allergan May Acquire Kandy Therapeutics 238

Allergan to Acquire Repros Therapeutics in Tender Offer 239

Allergan to Sell 10% Stake in Teva Pharma 241

Adcock Ingram to Acquire Genop 242

Paratek Pharma May Sell Itself 243

Allergan Enters into Option Arrangement to Acquire Lysosomal Therapeutics 245

Allergan Acquires Motus Therapeutics 246

Allergan Acquires Chase Pharma 247

Allergan Acquires Tobira Therapeutics in Tender Offer 248

Allergan Acquires Vitae Pharma in Tender Offer 250

Teva Pharma Acquires Anda from Allergan for USD500 Million 252

Allergan Acquires ForSight VISION5 253

Allergan Acquires RetroSense Therapeutics 254

Allergan Acquires Akarna Therapeutics 255

Carl Icahn Acquires Stake in Allergan 256

Allergan Acquires Topokine Therapeutics 257

Allergan Acquires Anterios 258

Allergan Acquires Kythera Biopharma for USD2.1 Billion 259

Allergan Acquires Naurex 261

Actavis Acquires Auden Mckenzie for USD458 Million 262

Actavis Acquires Allergan for USD70.5 Billion 263

Actavis May Acquire Almirall 265

Actavis Acquires Durata Therapeutics for USD675 Million in Tender Offer 266

Pfizer May Acquire Actavis 268

Forest Labs Completes Acquisition of Furiex Pharma 269

Actavis Completes Acquisition of Forest Labs for USD28 Billion 271

Actavis Acquires Silom Medical For USD 100 Million 273

Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For USD 2.9 Billion 274

Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 276

Actavis Completes Acquisition Of Warner Chilcott For USD 8.5 Billion 277

Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To USD 9.1 Million 280

Allergan Completes Acquisition Of MAP Pharma For USD 958 Million 281

Watson Pharma Acquires Uteron Pharma, Women's Health Company, For Up To USD 305 Million 283

Allergan Completes Acquisition Of SkinMedica, Skin Products Maker, For USD 350 Million 285

Watson Pharma Completes Acquisition Of Actavis Group For USD 5.92 Billion 287

Watson Pharma Sells Minority Stake In moksha8 Pharma For USD 47 Million 289

Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For USD 394 Million 290

SkinMedica Acquires Colorescience, Maker Of Skincare Products 292

Allergan Plc - Key Competitors 293

Allergan Plc - Key Employees 294

Allergan Plc - Locations And Subsidiaries 295

Head Office 295

Other Locations & Subsidiaries 295

Recent Developments 303

Financial Announcements 303

Apr 30, 2018: Allergan Reports 3% Increase in First Quarter 2018 GAAP Net Revenues to $3.7 Billion 303

Jan 08, 2018: Allergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan Conference 306

Nov 01, 2017: Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to $4.03 Billion 307

Aug 03, 2017: Allergan Reports Continued Strong Execution in Second Quarter 2017 with 9% Increase in GAAP Net Revenues to $4.0 Billion 311

May 09, 2017: Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion 315

Feb 08, 2017: Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016 319

Corporate Communications 323

Jun 14, 2018: Allergan Continues Active Board Refreshment Process 323

May 03, 2018: John Davidson Elected to Allergan Board of Directors 324

Feb 05, 2018: Allergan Appoints Matthew M. Walsh As Executive Vice President and Chief Financial Officer 325

Jan 04, 2018: Allergan to cut over 1,000 jobs to reduce costs 326

Sep 25, 2017: Allergan Announces Tessa Hilado, Executive Vice President and Chief Financial Officer, to Retire from Company 327

Sep 11, 2017: The Allergan Foundation to Donate $150,000 to Support Hurricane Irma Relief Efforts 328

Jul 19, 2017: Joseph H. Boccuzi Appointed to Allergan Board of Directors 329

Feb 27, 2017: Lisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan 330

Legal and Regulatory 331

Sep 11, 2017: Imprimis Releases Statement Regarding Allergan Lawsuit 331

Sep 07, 2017: Allergan Files Suits Against Imprimis Pharmaceuticals Prescriber's Choice and Sincerus Florida 332

May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 333

Government and Public Interest 334

Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 334

Feb 21, 2018: New report shines light on disconnect between patient and physicians when it comes to the seriousness of IBS, leading to slow diagnosis 336

Jan 23, 2017: Allergan Continues Commitment to Future of Headache Medicine with Educational Grants for Young Neurologists and Research Scientists 337

Product News 338

Jul 10, 2018: Allergan Expands REFRESH Portfolio With New REFRESH REPAIR Lubricant Eye Drops 338

05/01/2017: Allergan Announces Presentation on Cenicriviroc at Digestive Disease Week 2017 339

Product Approvals 340

Jul 19, 2017: Investigational New Drug Application for RTGel in Combination with BOTOX for the Treatment of Overactive Bladder Submitted to FDA by Allergan 340

Other Significant Developments 341

May 01, 2018: Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action 341

Sep 25, 2017: New Study Showcases Economic Impact of Allergan Operations on French Economy 342

Sep 12, 2017: Allergan Launches New Brilliant Distinctions Patient Loyalty Program 343

Appendix 344

Methodology 344

About GlobalData 344

Contact Us 344

Disclaimer 344


List Of Figure

List of Figures

Allergan Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14

Allergan Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 15

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 17

Allergan Plc, Medical Devices Deals, 2012 to YTD 2018 19


List Of Table

List of Tables

Allergan Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14

Allergan Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 15

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16

Allergan Plc, Deals By Therapy Area, 2012 to YTD 2018 17

Allergan Plc, Medical Devices Deals, 2012 to YTD 2018 19

Allergan Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 20

Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 33

Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 34

Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 36

Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For USD 55 Million 37

Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 38

Chase Pharma Raises USD12 Million in Financing Round 39

Chase Pharma Raises Additional USD0.5 Million in Venture Financing 40

Akarna Therapeutics Raises USD15 Million in Series B Financing 41

Rhythm Pharma Raises Additional USD15 Million in Series A Financing Round 42

RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 43

Chase Pharma Raises USD3 Million in Venture Financing 44

RetroSense Therapeutics Raises USD6 Million in Series A Financing 45

Naurex Raises USD80 Million in Series C Venture Financing 46

Colorescience Raises USD15 Million in Series B Venture Financing 48

Chase Pharma Raises USD21 Million in Series B Financing 49

Naurex Raises USD 25 Million In Venture Financing 50

Topokine Therapeutics Raises Funds Through Venture Financing 52

Rhythm Holding Raises USD 11 Million In Venture Financing 53

Colorescience Raises USD 10 Million In Series A Financing 54

Anterios Raises USD 8.5 Million In Venture Financing 55

Anterios Raises USD 4.7 Million In Venture Financing 56

Topokine Therapeutics Raises Funds Through Venture Financing 57

Colorescience Raises USD 15 Million In Venture Financing 58

Regado Biosciences Raises USD 51 Million In Series E Financing 59

Naurex Raises USD 38 Million In Series B Financing 61

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 63

Rhythm Pharma Raises USD 33 Million In Series B Financing 65

Rhythm Pharma Raises USD 9.5 Million In Venture Financing 67

Uteron Pharma Raises USD 10.4 Million In Venture Financing 68

Regado Biosciences Raises USD 6.8 Million In Venture Financing 69

Motus Therapeutics Secures USD25 Million in Series B Round of Venture Funding 70

Uteron Pharma Raises USD 19 Million In Venture Financing 71

SkinMedica Raises USD 16.8 Million In Venture Financing 72

Allergan May Divest its Women's Health Business 73

TPG Capital Acquires Aptalis Pharma from Actavis 74

Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 75

Lyndra Enters into Agreement with Allergan 76

Allergan to Enter into Partnership with Target PharmaSolutions 77

Allergan Enters into Agreement with Novartis 78

Allergan Pharma Enters into Research Agreement with Editas Medicine 79

Gedeon Richter Enters into Distribution Agreement with Allergan 80

T2 Biosystems Enters into Agreement with Allergan 81

Amgen Enters into Agreement with Allergan 82

Allergan Enters into Co-Development Agreement with AstraZeneca 83

Galderma Enters into Agreement with ZELTIQ Aesthetics 84

Allergan Enters into Agreement with Rugen Therapeutics 85

Allergan Enters into Research Agreement with Humana 86

NuMedii Enters into Research Agreement with Allergan 87

Aptinyx to Enter into Research Partnership with Allergan 88

Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 89

Molecular Partners Reinforces Partnership with Allergan 90

Allergan Enters into Distribution Agreement with WhanIn Pharma 91

Particle Sciences Enters Into Co-Development Agreement With Actavis 92

Voyant Biotherapeutics Enters Into R&D Agreement With Allergan For Ocular Disease 93

Merrimack Pharma Amends Co-Development Agreement With Actavis 94

Amerigen Pharma Enters Into Co-Development Agreement With Forest Labs For Specialty Generic Products 95

Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 96

Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 97

Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 98

Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 99

Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 100

Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 101

Allergan Exercises Option Agreement with Molecular Partners 102

American Medical Systems Enters Into Co-Development Agreement With Allergan 103

Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 104

ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 105

Regado Biosciences Merges with Tobira Therapeutics 106

Syndax Pharma Enters into Licensing Agreement with Vitae Pharma 108

Allergan Enters into Licensing Agreement with Saint Regis Mohawk Tribe 109

Allergan Enters into Licensing Agreement with Assembly Biosciences 110

Allergan Enters Into Licensing Agreement With UroGen Pharma 112

Allergan Enters into Licensing Agreement with AstraZeneca 113

RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 114

Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 115

Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 116

Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 117

Allergan Amends Licensing Agreement with Heptares Therapeutics 118

Rhythm Pharma Enters into Licensing Agreement with Camurus 119

Allergan Enters into Licensing Agreement with Mimetogen Pharma 120

Allergan Enters into Licensing Agreement with Almirall for Constella 121

Apricus Biosciences Enters into Licensing Agreement with Allergan 122

Allergan Enters into Licensing Agreement with Merck 123

Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 124

Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 125

Durata Therapeutics Enters into Licensing Agreement with Angelini for Dalvance 126

Allergan Enters Into Licensing Agreement With Medytox For Neurotoxin Product 127

RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 128

Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 129

Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 130

Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 131

Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 132

Angelini Enters into Licensing Agreement with Allergan 133

Forest Labs Amends Licensing Agreement With moksha8 For Viibryd 134

InnoCore Enters Into Licensing Agreement With Allergan 135

Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 136

Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 137

Watson Pharma Enters Into Licensing Agreement With moksha8 Pharma For Five Generic Central Nervous System Products 138

Forest Labs Enters Into Licensing Agreement With moksha8 For Viibryd 139

Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 140

QrxPharma Enters Into Licensing Agreement With Actavis For MoxDuo IR 141

Allergan Files Registration Statement for Public Offering of Securities 143

Vitae Pharma Raises USD35 Million in Public Offering of Shares 144

Aptinyx Spin Off from Naurex 146

Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 147

Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 148

Anterios Postpones IPO for up to USD54.6 Million 149

Kythera Biopharma Raises USD143.8 Million in Public Offering of Shares 150

Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 152

Actavis Raises USD4.18 Billion in Public Offering of Shares 154

Vitae Pharma Raises USD41 Million in Public Offering of Shares 156

Vitae Pharmaceuticals Completes Exercise of Underwriter's Over Allotment Option for IPO for USD63.3 Million 158

Tobira Therapeutics Withdraws IPO 160

Regado Biosciences Completes Public Offering Of Shares For USD 60 Million 162

Regado Biosciences Completes Private Placement Of Shares For USD 20 Million 164

Furiex Pharma Files Registration Statement For Public Offering Of Securities For USD 100 Million 165

Kythera Biopharma Completes Underwriters' Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 133.5 Million 166

Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For USD 43 Million 168

Durata Therapeutics Completes Public Offering Of Shares For USD 58 Million 170

Kythera Biopharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 81 Million 172

MAP Pharma Completes Public Offering Of Common Stock For USD 60 Million 174

Forest Labs Plans Rights Offering Of Common Stock 175

Durata Therapeutics Completes IPO For USD 78 Million 176

Allergan Raises USD817.8 Million in Public Offering of 0.5% Notes Due 2021 178

Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 179

Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 180

Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 181

Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 182

Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2045 183

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2016 185

Actavis Raises USD4 Billion in Public Offering of Senior Notes Due 2025 187

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2020 189

Actavis Raises USD1 Billion in Public Offering of Senior Notes Due 2017 191

Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2022 193

Actavis Raises USD3.5 Billion in Public Offering of Senior Notes Due 2020 195

Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2035 197

Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2018 199

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2018 201

Forest Lab Completes Private Placement Of Notes Due 2021 For USD 750 Million 203

Forest Lab Completes Private Placement Of Notes Due 2019 For USD 1.05 Billion 204

Forest Labs Completes Private Placement Of Notes Due 2021 For USD 1.2 Billion 205

Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For USD 25 Million 206

Watson Pharma Completes Public Offering Of Notes Due 2022 For USD 1.7 Billion 207

Watson Pharma Completes Public Offering Of Notes Due 2017 For USD 1.2 Billion 209

Watson Pharma Completes Public Offering Of Notes Due 2042 For USD 1 Billion 211

Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 213

Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 215

Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 217

Ropack Acquires Two Pharma Facilities in Long Island, New York from Forest Labs 219

AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 220

Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 221

Mithra Pharma Acquires Women Health Portfolio from Uteron Pharma 222

Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 223

Impax Labs Acquires Two Generic Products from Actavis 224

G&W Labs Acquires Facility in Lincoln County, North Carolina from Actavis 225

Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For USD 40.8 Million 226

Mayne Pharma Acquires Brands And Related Assets For Forest Labs For USD 12 Million 228

Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 229

Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 231

Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 233

Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 234

Harvard Drug Group Completes Acquisition Of Rugby OTC Portfolio Of Watson Pharma For USD 117 Million 236

Allergan May Acquire Kandy Therapeutics 238

Allergan to Acquire Repros Therapeutics in Tender Offer 239

Allergan to Sell 10% Stake in Teva Pharma 241

Adcock Ingram to Acquire Genop 242

Paratek Pharma May Sell Itself 243

Allergan Enters into Option Arrangement to Acquire Lysosomal Therapeutics 245

Allergan Acquires Motus Therapeutics 246

Allergan Acquires Chase Pharma 247

Allergan Acquires Tobira Therapeutics in Tender Offer 248

Allergan Acquires Vitae Pharma in Tender Offer 250

Teva Pharma Acquires Anda from Allergan for USD500 Million 252

Allergan Acquires ForSight VISION5 253

Allergan Acquires RetroSense Therapeutics 254

Allergan Acquires Akarna Therapeutics 255

Carl Icahn Acquires Stake in Allergan 256

Allergan Acquires Topokine Therapeutics 257

Allergan Acquires Anterios 258

Allergan Acquires Kythera Biopharma for USD2.1 Billion 259

Allergan Acquires Naurex 261

Actavis Acquires Auden Mckenzie for USD458 Million 262

Actavis Acquires Allergan for USD70.5 Billion 263

Actavis May Acquire Almirall 265

Actavis Acquires Durata Therapeutics for USD675 Million in Tender Offer 266

Pfizer May Acquire Actavis 268

Forest Labs Completes Acquisition of Furiex Pharma 269

Actavis Completes Acquisition of Forest Labs for USD28 Billion 271

Actavis Acquires Silom Medical For USD 100 Million 273

Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For USD 2.9 Billion 274

Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 276

Actavis Completes Acquisition Of Warner Chilcott For USD 8.5 Billion 277

Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To USD 9.1 Million 280

Allergan Completes Acquisition Of MAP Pharma For USD 958 Million 281

Watson Pharma Acquires Uteron Pharma, Women's Health Company, For Up To USD 305 Million 283

Allergan Completes Acquisition Of SkinMedica, Skin Products Maker, For USD 350 Million 285

Watson Pharma Completes Acquisition Of Actavis Group For USD 5.92 Billion 287

Watson Pharma Sells Minority Stake In moksha8 Pharma For USD 47 Million 289

Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For USD 394 Million 290

SkinMedica Acquires Colorescience, Maker Of Skincare Products 292

Allergan Plc, Key Competitors 293

Allergan Plc, Key Employees 294

Allergan Plc, Other Locations 295

Allergan Plc, Subsidiaries 295

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Allergan Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology, women's health, urology and anti-infective therapeutic categories. The company sells its products to retailers, drug wholesalers and distributors, including national retail drug and food store chains, mail order retailers, hospitals, clinics, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. It has operations in several countries across the Americas, Europe, Asia-Pacific, the Middle East and Africa. Allergan is headquartered in Dublin, Ireland.

Allergan Plc (AGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 9

List of Figures 12

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14

Allergan Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 15

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 17

Allergan Plc, Medical Devices Deals, 2012 to YTD 2018 19

Allergan Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 20

Allergan Plc, Pharmaceuticals & Healthcare, Deal Details 33

Asset Purchase 33

Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 33

Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 34

Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 36

Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For USD 55 Million 37

Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 38

Venture Financing 39

Chase Pharma Raises USD12 Million in Financing Round 39

Chase Pharma Raises Additional USD0.5 Million in Venture Financing 40

Akarna Therapeutics Raises USD15 Million in Series B Financing 41

Rhythm Pharma Raises Additional USD15 Million in Series A Financing Round 42

RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 43

Chase Pharma Raises USD3 Million in Venture Financing 44

RetroSense Therapeutics Raises USD6 Million in Series A Financing 45

Naurex Raises USD80 Million in Series C Venture Financing 46

Colorescience Raises USD15 Million in Series B Venture Financing 48

Chase Pharma Raises USD21 Million in Series B Financing 49

Naurex Raises USD 25 Million In Venture Financing 50

Topokine Therapeutics Raises Funds Through Venture Financing 52

Rhythm Holding Raises USD 11 Million In Venture Financing 53

Colorescience Raises USD 10 Million In Series A Financing 54

Anterios Raises USD 8.5 Million In Venture Financing 55

Anterios Raises USD 4.7 Million In Venture Financing 56

Topokine Therapeutics Raises Funds Through Venture Financing 57

Colorescience Raises USD 15 Million In Venture Financing 58

Regado Biosciences Raises USD 51 Million In Series E Financing 59

Naurex Raises USD 38 Million In Series B Financing 61

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 63

Rhythm Pharma Raises USD 33 Million In Series B Financing 65

Rhythm Pharma Raises USD 9.5 Million In Venture Financing 67

Uteron Pharma Raises USD 10.4 Million In Venture Financing 68

Regado Biosciences Raises USD 6.8 Million In Venture Financing 69

Motus Therapeutics Secures USD25 Million in Series B Round of Venture Funding 70

Uteron Pharma Raises USD 19 Million In Venture Financing 71

SkinMedica Raises USD 16.8 Million In Venture Financing 72

Private Equity 73

Allergan May Divest its Women's Health Business 73

TPG Capital Acquires Aptalis Pharma from Actavis 74

Partnerships 75

Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 75

Lyndra Enters into Agreement with Allergan 76

Allergan to Enter into Partnership with Target PharmaSolutions 77

Allergan Enters into Agreement with Novartis 78

Allergan Pharma Enters into Research Agreement with Editas Medicine 79

Gedeon Richter Enters into Distribution Agreement with Allergan 80

T2 Biosystems Enters into Agreement with Allergan 81

Amgen Enters into Agreement with Allergan 82

Allergan Enters into Co-Development Agreement with AstraZeneca 83

Galderma Enters into Agreement with ZELTIQ Aesthetics 84

Allergan Enters into Agreement with Rugen Therapeutics 85

Allergan Enters into Research Agreement with Humana 86

NuMedii Enters into Research Agreement with Allergan 87

Aptinyx to Enter into Research Partnership with Allergan 88

Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 89

Molecular Partners Reinforces Partnership with Allergan 90

Allergan Enters into Distribution Agreement with WhanIn Pharma 91

Particle Sciences Enters Into Co-Development Agreement With Actavis 92

Voyant Biotherapeutics Enters Into R&D Agreement With Allergan For Ocular Disease 93

Merrimack Pharma Amends Co-Development Agreement With Actavis 94

Amerigen Pharma Enters Into Co-Development Agreement With Forest Labs For Specialty Generic Products 95

Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 96

Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 97

Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 98

Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 99

Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 100

Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 101

Allergan Exercises Option Agreement with Molecular Partners 102

American Medical Systems Enters Into Co-Development Agreement With Allergan 103

Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 104

ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 105

Merger 106

Regado Biosciences Merges with Tobira Therapeutics 106

Licensing Agreements 108

Syndax Pharma Enters into Licensing Agreement with Vitae Pharma 108

Allergan Enters into Licensing Agreement with Saint Regis Mohawk Tribe 109

Allergan Enters into Licensing Agreement with Assembly Biosciences 110

Allergan Enters Into Licensing Agreement With UroGen Pharma 112

Allergan Enters into Licensing Agreement with AstraZeneca 113

RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 114

Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 115

Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 116

Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 117

Allergan Amends Licensing Agreement with Heptares Therapeutics 118

Rhythm Pharma Enters into Licensing Agreement with Camurus 119

Allergan Enters into Licensing Agreement with Mimetogen Pharma 120

Allergan Enters into Licensing Agreement with Almirall for Constella 121

Apricus Biosciences Enters into Licensing Agreement with Allergan 122

Allergan Enters into Licensing Agreement with Merck 123

Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 124

Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 125

Durata Therapeutics Enters into Licensing Agreement with Angelini for Dalvance 126

Allergan Enters Into Licensing Agreement With Medytox For Neurotoxin Product 127

RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 128

Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 129

Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 130

Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 131

Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 132

Angelini Enters into Licensing Agreement with Allergan 133

Forest Labs Amends Licensing Agreement With moksha8 For Viibryd 134

InnoCore Enters Into Licensing Agreement With Allergan 135

Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 136

Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 137

Watson Pharma Enters Into Licensing Agreement With moksha8 Pharma For Five Generic Central Nervous System Products 138

Forest Labs Enters Into Licensing Agreement With moksha8 For Viibryd 139

Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 140

QrxPharma Enters Into Licensing Agreement With Actavis For MoxDuo IR 141

Equity Offering 143

Allergan Files Registration Statement for Public Offering of Securities 143

Vitae Pharma Raises USD35 Million in Public Offering of Shares 144

Aptinyx Spin Off from Naurex 146

Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 147

Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 148

Anterios Postpones IPO for up to USD54.6 Million 149

Kythera Biopharma Raises USD143.8 Million in Public Offering of Shares 150

Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 152

Actavis Raises USD4.18 Billion in Public Offering of Shares 154

Vitae Pharma Raises USD41 Million in Public Offering of Shares 156

Vitae Pharmaceuticals Completes Exercise of Underwriter's Over Allotment Option for IPO for USD63.3 Million 158

Tobira Therapeutics Withdraws IPO 160

Regado Biosciences Completes Public Offering Of Shares For USD 60 Million 162

Regado Biosciences Completes Private Placement Of Shares For USD 20 Million 164

Furiex Pharma Files Registration Statement For Public Offering Of Securities For USD 100 Million 165

Kythera Biopharma Completes Underwriters' Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 133.5 Million 166

Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For USD 43 Million 168

Durata Therapeutics Completes Public Offering Of Shares For USD 58 Million 170

Kythera Biopharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 81 Million 172

MAP Pharma Completes Public Offering Of Common Stock For USD 60 Million 174

Forest Labs Plans Rights Offering Of Common Stock 175

Durata Therapeutics Completes IPO For USD 78 Million 176

Debt Offering 178

Allergan Raises USD817.8 Million in Public Offering of 0.5% Notes Due 2021 178

Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 179

Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 180

Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 181

Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 182

Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2045 183

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2016 185

Actavis Raises USD4 Billion in Public Offering of Senior Notes Due 2025 187

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2020 189

Actavis Raises USD1 Billion in Public Offering of Senior Notes Due 2017 191

Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2022 193

Actavis Raises USD3.5 Billion in Public Offering of Senior Notes Due 2020 195

Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2035 197

Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2018 199

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2018 201

Forest Lab Completes Private Placement Of Notes Due 2021 For USD 750 Million 203

Forest Lab Completes Private Placement Of Notes Due 2019 For USD 1.05 Billion 204

Forest Labs Completes Private Placement Of Notes Due 2021 For USD 1.2 Billion 205

Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For USD 25 Million 206

Watson Pharma Completes Public Offering Of Notes Due 2022 For USD 1.7 Billion 207

Watson Pharma Completes Public Offering Of Notes Due 2017 For USD 1.2 Billion 209

Watson Pharma Completes Public Offering Of Notes Due 2042 For USD 1 Billion 211

Asset Transactions 213

Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 213

Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 215

Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 217

Ropack Acquires Two Pharma Facilities in Long Island, New York from Forest Labs 219

AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 220

Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 221

Mithra Pharma Acquires Women Health Portfolio from Uteron Pharma 222

Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 223

Impax Labs Acquires Two Generic Products from Actavis 224

G&W Labs Acquires Facility in Lincoln County, North Carolina from Actavis 225

Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For USD 40.8 Million 226

Mayne Pharma Acquires Brands And Related Assets For Forest Labs For USD 12 Million 228

Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 229

Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 231

Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 233

Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 234

Harvard Drug Group Completes Acquisition Of Rugby OTC Portfolio Of Watson Pharma For USD 117 Million 236

Acquisition 238

Allergan May Acquire Kandy Therapeutics 238

Allergan to Acquire Repros Therapeutics in Tender Offer 239

Allergan to Sell 10% Stake in Teva Pharma 241

Adcock Ingram to Acquire Genop 242

Paratek Pharma May Sell Itself 243

Allergan Enters into Option Arrangement to Acquire Lysosomal Therapeutics 245

Allergan Acquires Motus Therapeutics 246

Allergan Acquires Chase Pharma 247

Allergan Acquires Tobira Therapeutics in Tender Offer 248

Allergan Acquires Vitae Pharma in Tender Offer 250

Teva Pharma Acquires Anda from Allergan for USD500 Million 252

Allergan Acquires ForSight VISION5 253

Allergan Acquires RetroSense Therapeutics 254

Allergan Acquires Akarna Therapeutics 255

Carl Icahn Acquires Stake in Allergan 256

Allergan Acquires Topokine Therapeutics 257

Allergan Acquires Anterios 258

Allergan Acquires Kythera Biopharma for USD2.1 Billion 259

Allergan Acquires Naurex 261

Actavis Acquires Auden Mckenzie for USD458 Million 262

Actavis Acquires Allergan for USD70.5 Billion 263

Actavis May Acquire Almirall 265

Actavis Acquires Durata Therapeutics for USD675 Million in Tender Offer 266

Pfizer May Acquire Actavis 268

Forest Labs Completes Acquisition of Furiex Pharma 269

Actavis Completes Acquisition of Forest Labs for USD28 Billion 271

Actavis Acquires Silom Medical For USD 100 Million 273

Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For USD 2.9 Billion 274

Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 276

Actavis Completes Acquisition Of Warner Chilcott For USD 8.5 Billion 277

Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To USD 9.1 Million 280

Allergan Completes Acquisition Of MAP Pharma For USD 958 Million 281

Watson Pharma Acquires Uteron Pharma, Women's Health Company, For Up To USD 305 Million 283

Allergan Completes Acquisition Of SkinMedica, Skin Products Maker, For USD 350 Million 285

Watson Pharma Completes Acquisition Of Actavis Group For USD 5.92 Billion 287

Watson Pharma Sells Minority Stake In moksha8 Pharma For USD 47 Million 289

Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For USD 394 Million 290

SkinMedica Acquires Colorescience, Maker Of Skincare Products 292

Allergan Plc - Key Competitors 293

Allergan Plc - Key Employees 294

Allergan Plc - Locations And Subsidiaries 295

Head Office 295

Other Locations & Subsidiaries 295

Recent Developments 303

Financial Announcements 303

Apr 30, 2018: Allergan Reports 3% Increase in First Quarter 2018 GAAP Net Revenues to $3.7 Billion 303

Jan 08, 2018: Allergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan Conference 306

Nov 01, 2017: Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to $4.03 Billion 307

Aug 03, 2017: Allergan Reports Continued Strong Execution in Second Quarter 2017 with 9% Increase in GAAP Net Revenues to $4.0 Billion 311

May 09, 2017: Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion 315

Feb 08, 2017: Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016 319

Corporate Communications 323

Jun 14, 2018: Allergan Continues Active Board Refreshment Process 323

May 03, 2018: John Davidson Elected to Allergan Board of Directors 324

Feb 05, 2018: Allergan Appoints Matthew M. Walsh As Executive Vice President and Chief Financial Officer 325

Jan 04, 2018: Allergan to cut over 1,000 jobs to reduce costs 326

Sep 25, 2017: Allergan Announces Tessa Hilado, Executive Vice President and Chief Financial Officer, to Retire from Company 327

Sep 11, 2017: The Allergan Foundation to Donate $150,000 to Support Hurricane Irma Relief Efforts 328

Jul 19, 2017: Joseph H. Boccuzi Appointed to Allergan Board of Directors 329

Feb 27, 2017: Lisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan 330

Legal and Regulatory 331

Sep 11, 2017: Imprimis Releases Statement Regarding Allergan Lawsuit 331

Sep 07, 2017: Allergan Files Suits Against Imprimis Pharmaceuticals Prescriber's Choice and Sincerus Florida 332

May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 333

Government and Public Interest 334

Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 334

Feb 21, 2018: New report shines light on disconnect between patient and physicians when it comes to the seriousness of IBS, leading to slow diagnosis 336

Jan 23, 2017: Allergan Continues Commitment to Future of Headache Medicine with Educational Grants for Young Neurologists and Research Scientists 337

Product News 338

Jul 10, 2018: Allergan Expands REFRESH Portfolio With New REFRESH REPAIR Lubricant Eye Drops 338

05/01/2017: Allergan Announces Presentation on Cenicriviroc at Digestive Disease Week 2017 339

Product Approvals 340

Jul 19, 2017: Investigational New Drug Application for RTGel in Combination with BOTOX for the Treatment of Overactive Bladder Submitted to FDA by Allergan 340

Other Significant Developments 341

May 01, 2018: Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action 341

Sep 25, 2017: New Study Showcases Economic Impact of Allergan Operations on French Economy 342

Sep 12, 2017: Allergan Launches New Brilliant Distinctions Patient Loyalty Program 343

Appendix 344

Methodology 344

About GlobalData 344

Contact Us 344

Disclaimer 344


List Of Figure

List of Figures

Allergan Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14

Allergan Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 15

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 17

Allergan Plc, Medical Devices Deals, 2012 to YTD 2018 19


List Of Table

List of Tables

Allergan Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14

Allergan Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 15

Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16

Allergan Plc, Deals By Therapy Area, 2012 to YTD 2018 17

Allergan Plc, Medical Devices Deals, 2012 to YTD 2018 19

Allergan Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 20

Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 33

Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 34

Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 36

Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For USD 55 Million 37

Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 38

Chase Pharma Raises USD12 Million in Financing Round 39

Chase Pharma Raises Additional USD0.5 Million in Venture Financing 40

Akarna Therapeutics Raises USD15 Million in Series B Financing 41

Rhythm Pharma Raises Additional USD15 Million in Series A Financing Round 42

RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 43

Chase Pharma Raises USD3 Million in Venture Financing 44

RetroSense Therapeutics Raises USD6 Million in Series A Financing 45

Naurex Raises USD80 Million in Series C Venture Financing 46

Colorescience Raises USD15 Million in Series B Venture Financing 48

Chase Pharma Raises USD21 Million in Series B Financing 49

Naurex Raises USD 25 Million In Venture Financing 50

Topokine Therapeutics Raises Funds Through Venture Financing 52

Rhythm Holding Raises USD 11 Million In Venture Financing 53

Colorescience Raises USD 10 Million In Series A Financing 54

Anterios Raises USD 8.5 Million In Venture Financing 55

Anterios Raises USD 4.7 Million In Venture Financing 56

Topokine Therapeutics Raises Funds Through Venture Financing 57

Colorescience Raises USD 15 Million In Venture Financing 58

Regado Biosciences Raises USD 51 Million In Series E Financing 59

Naurex Raises USD 38 Million In Series B Financing 61

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 63

Rhythm Pharma Raises USD 33 Million In Series B Financing 65

Rhythm Pharma Raises USD 9.5 Million In Venture Financing 67

Uteron Pharma Raises USD 10.4 Million In Venture Financing 68

Regado Biosciences Raises USD 6.8 Million In Venture Financing 69

Motus Therapeutics Secures USD25 Million in Series B Round of Venture Funding 70

Uteron Pharma Raises USD 19 Million In Venture Financing 71

SkinMedica Raises USD 16.8 Million In Venture Financing 72

Allergan May Divest its Women's Health Business 73

TPG Capital Acquires Aptalis Pharma from Actavis 74

Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 75

Lyndra Enters into Agreement with Allergan 76

Allergan to Enter into Partnership with Target PharmaSolutions 77

Allergan Enters into Agreement with Novartis 78

Allergan Pharma Enters into Research Agreement with Editas Medicine 79

Gedeon Richter Enters into Distribution Agreement with Allergan 80

T2 Biosystems Enters into Agreement with Allergan 81

Amgen Enters into Agreement with Allergan 82

Allergan Enters into Co-Development Agreement with AstraZeneca 83

Galderma Enters into Agreement with ZELTIQ Aesthetics 84

Allergan Enters into Agreement with Rugen Therapeutics 85

Allergan Enters into Research Agreement with Humana 86

NuMedii Enters into Research Agreement with Allergan 87

Aptinyx to Enter into Research Partnership with Allergan 88

Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 89

Molecular Partners Reinforces Partnership with Allergan 90

Allergan Enters into Distribution Agreement with WhanIn Pharma 91

Particle Sciences Enters Into Co-Development Agreement With Actavis 92

Voyant Biotherapeutics Enters Into R&D Agreement With Allergan For Ocular Disease 93

Merrimack Pharma Amends Co-Development Agreement With Actavis 94

Amerigen Pharma Enters Into Co-Development Agreement With Forest Labs For Specialty Generic Products 95

Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 96

Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 97

Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 98

Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 99

Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 100

Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 101

Allergan Exercises Option Agreement with Molecular Partners 102

American Medical Systems Enters Into Co-Development Agreement With Allergan 103

Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 104

ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 105

Regado Biosciences Merges with Tobira Therapeutics 106

Syndax Pharma Enters into Licensing Agreement with Vitae Pharma 108

Allergan Enters into Licensing Agreement with Saint Regis Mohawk Tribe 109

Allergan Enters into Licensing Agreement with Assembly Biosciences 110

Allergan Enters Into Licensing Agreement With UroGen Pharma 112

Allergan Enters into Licensing Agreement with AstraZeneca 113

RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 114

Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 115

Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 116

Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 117

Allergan Amends Licensing Agreement with Heptares Therapeutics 118

Rhythm Pharma Enters into Licensing Agreement with Camurus 119

Allergan Enters into Licensing Agreement with Mimetogen Pharma 120

Allergan Enters into Licensing Agreement with Almirall for Constella 121

Apricus Biosciences Enters into Licensing Agreement with Allergan 122

Allergan Enters into Licensing Agreement with Merck 123

Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 124

Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 125

Durata Therapeutics Enters into Licensing Agreement with Angelini for Dalvance 126

Allergan Enters Into Licensing Agreement With Medytox For Neurotoxin Product 127

RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 128

Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 129

Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 130

Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 131

Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 132

Angelini Enters into Licensing Agreement with Allergan 133

Forest Labs Amends Licensing Agreement With moksha8 For Viibryd 134

InnoCore Enters Into Licensing Agreement With Allergan 135

Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 136

Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 137

Watson Pharma Enters Into Licensing Agreement With moksha8 Pharma For Five Generic Central Nervous System Products 138

Forest Labs Enters Into Licensing Agreement With moksha8 For Viibryd 139

Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 140

QrxPharma Enters Into Licensing Agreement With Actavis For MoxDuo IR 141

Allergan Files Registration Statement for Public Offering of Securities 143

Vitae Pharma Raises USD35 Million in Public Offering of Shares 144

Aptinyx Spin Off from Naurex 146

Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 147

Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 148

Anterios Postpones IPO for up to USD54.6 Million 149

Kythera Biopharma Raises USD143.8 Million in Public Offering of Shares 150

Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 152

Actavis Raises USD4.18 Billion in Public Offering of Shares 154

Vitae Pharma Raises USD41 Million in Public Offering of Shares 156

Vitae Pharmaceuticals Completes Exercise of Underwriter's Over Allotment Option for IPO for USD63.3 Million 158

Tobira Therapeutics Withdraws IPO 160

Regado Biosciences Completes Public Offering Of Shares For USD 60 Million 162

Regado Biosciences Completes Private Placement Of Shares For USD 20 Million 164

Furiex Pharma Files Registration Statement For Public Offering Of Securities For USD 100 Million 165

Kythera Biopharma Completes Underwriters' Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 133.5 Million 166

Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For USD 43 Million 168

Durata Therapeutics Completes Public Offering Of Shares For USD 58 Million 170

Kythera Biopharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 81 Million 172

MAP Pharma Completes Public Offering Of Common Stock For USD 60 Million 174

Forest Labs Plans Rights Offering Of Common Stock 175

Durata Therapeutics Completes IPO For USD 78 Million 176

Allergan Raises USD817.8 Million in Public Offering of 0.5% Notes Due 2021 178

Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 179

Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 180

Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 181

Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 182

Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2045 183

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2016 185

Actavis Raises USD4 Billion in Public Offering of Senior Notes Due 2025 187

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2020 189

Actavis Raises USD1 Billion in Public Offering of Senior Notes Due 2017 191

Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2022 193

Actavis Raises USD3.5 Billion in Public Offering of Senior Notes Due 2020 195

Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2035 197

Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2018 199

Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2018 201

Forest Lab Completes Private Placement Of Notes Due 2021 For USD 750 Million 203

Forest Lab Completes Private Placement Of Notes Due 2019 For USD 1.05 Billion 204

Forest Labs Completes Private Placement Of Notes Due 2021 For USD 1.2 Billion 205

Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For USD 25 Million 206

Watson Pharma Completes Public Offering Of Notes Due 2022 For USD 1.7 Billion 207

Watson Pharma Completes Public Offering Of Notes Due 2017 For USD 1.2 Billion 209

Watson Pharma Completes Public Offering Of Notes Due 2042 For USD 1 Billion 211

Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 213

Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 215

Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 217

Ropack Acquires Two Pharma Facilities in Long Island, New York from Forest Labs 219

AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 220

Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 221

Mithra Pharma Acquires Women Health Portfolio from Uteron Pharma 222

Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 223

Impax Labs Acquires Two Generic Products from Actavis 224

G&W Labs Acquires Facility in Lincoln County, North Carolina from Actavis 225

Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For USD 40.8 Million 226

Mayne Pharma Acquires Brands And Related Assets For Forest Labs For USD 12 Million 228

Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 229

Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 231

Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 233

Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 234

Harvard Drug Group Completes Acquisition Of Rugby OTC Portfolio Of Watson Pharma For USD 117 Million 236

Allergan May Acquire Kandy Therapeutics 238

Allergan to Acquire Repros Therapeutics in Tender Offer 239

Allergan to Sell 10% Stake in Teva Pharma 241

Adcock Ingram to Acquire Genop 242

Paratek Pharma May Sell Itself 243

Allergan Enters into Option Arrangement to Acquire Lysosomal Therapeutics 245

Allergan Acquires Motus Therapeutics 246

Allergan Acquires Chase Pharma 247

Allergan Acquires Tobira Therapeutics in Tender Offer 248

Allergan Acquires Vitae Pharma in Tender Offer 250

Teva Pharma Acquires Anda from Allergan for USD500 Million 252

Allergan Acquires ForSight VISION5 253

Allergan Acquires RetroSense Therapeutics 254

Allergan Acquires Akarna Therapeutics 255

Carl Icahn Acquires Stake in Allergan 256

Allergan Acquires Topokine Therapeutics 257

Allergan Acquires Anterios 258

Allergan Acquires Kythera Biopharma for USD2.1 Billion 259

Allergan Acquires Naurex 261

Actavis Acquires Auden Mckenzie for USD458 Million 262

Actavis Acquires Allergan for USD70.5 Billion 263

Actavis May Acquire Almirall 265

Actavis Acquires Durata Therapeutics for USD675 Million in Tender Offer 266

Pfizer May Acquire Actavis 268

Forest Labs Completes Acquisition of Furiex Pharma 269

Actavis Completes Acquisition of Forest Labs for USD28 Billion 271

Actavis Acquires Silom Medical For USD 100 Million 273

Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For USD 2.9 Billion 274

Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 276

Actavis Completes Acquisition Of Warner Chilcott For USD 8.5 Billion 277

Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To USD 9.1 Million 280

Allergan Completes Acquisition Of MAP Pharma For USD 958 Million 281

Watson Pharma Acquires Uteron Pharma, Women's Health Company, For Up To USD 305 Million 283

Allergan Completes Acquisition Of SkinMedica, Skin Products Maker, For USD 350 Million 285

Watson Pharma Completes Acquisition Of Actavis Group For USD 5.92 Billion 287

Watson Pharma Sells Minority Stake In moksha8 Pharma For USD 47 Million 289

Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For USD 394 Million 290

SkinMedica Acquires Colorescience, Maker Of Skincare Products 292

Allergan Plc, Key Competitors 293

Allergan Plc, Key Employees 294

Allergan Plc, Other Locations 295

Allergan Plc, Subsidiaries 295

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Allergan Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.